Publication: Conditional survival after radical cystectomy for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder: a population-based analysis
Program
KU-Authors
KU Authors
Co-Authors
Barletta, Francesco
Tappero, Stefano
Panunzio, Andrea
Incesu, Reha-Baris
Garcia, Cristina Cano
Piccinelli, Mattia Luca
Tian, The
Gandaglia, Giorgio
Moschini, Marco
Terrone, Carlo
Advisor
Publication Date
2023
Language
en
Type
Journal article
Journal Title
Journal ISSN
Volume Title
Abstract
Purpose: To assess the effect of event-free survival duration on cancer-specific mortality (CSM) after radical cystectomy (RC) in nonmetastatic muscle-invasive squamous cell carcinoma of the urinary bladder. Methods: RC patients treated for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder were identified within the Surveillance, Epidemiology, and End Results database (2000-2018). Independent predictor status for CSM of T and N stage groupings (i.e., T2N0, T3N0, T4N0, and TanyN1-3) was tested in multivariable Cox-regression models. Conditional 5-year CSM-free estimates were assessed at baseline and at 4 specific event-free survival times (i.e. 6, 12, 18 and 24 months), within each of the 4 examined stage groups. Results: Of 981 RC patients, 206 (21%), 416 (42%), 152 (16%), and 207 (21%) were T2N0, T3N0, T4N0, and TanyN1-3, respectively. In multivariable Cox-regression models T3N0 (HR 1.94), T4N0 (HR 5.22), and TanyN1-3 (HR 6.62) were independent predictors of CSM, relative to T2N0. In conditional survival analyses based on 24 months event-free status, survival estimates were: 89% for T2N0 vs. 76% at baseline (Delta = 13%), 84% for T3N0 vs. 58% at baseline (Delta = 26%), 69% for T4N0 vs. 25% at baseline (Delta = 44%), 69% for TanyN1-3 vs. 22% at baseline (Delta = 47%). Conclusions: Event-free status at 24 months of follow-up is associated with substantially higher CSM-free survival than when CSM-free survival is predicted at baseline. The magnitude of this effect is most pronounced in TanyN1-3 and T4N0 patients, intermediate in T3N0 and more modest, nonetheless important, in T2N0.
Description
Source:
Urologic Oncology-Seminars and Original Investigations
Publisher:
Elsevier Science Inc
Keywords:
Subject
Oncology, Urology, Nephrology